Asfotase alfa

Details

Files

Generic Name:

Asfotase alfa

Project Status:

Complete

Therapeutic Area:

Hypophosphatasia, pediatric-onset

Manufacturer:

Alexion Pharmaceuticals Canada

Call for patient/clinician input open:

July 20, 2015

Brand Name:

Strensiq

Project Line:

Reimbursement Review

Project Number:

SR0443-000

Call for patient/clinician input closed:

September 9, 2015

NOC Status at Filing:

Post NOC

Submission Type:

Initial

Indications:

Hypophosphatasia, pediatric-onset

Recommendation Type:

List with criteria/condition

Final Recommendation:

March 23, 2016

Files

Submission Status Report View PDF

Recommendation and Reasons View PDF

Patient Group Input Submissions View PDF

Clinical Report View PDF

Pharmacoeconomic Report View PDF

Last Updated : July 20, 2015